FTSE 100 rises as investors cheer easing US recession fears
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Admiral gains after H1 profit beat, special dividend
Industrial metal miners lag as heavyweights go ex-div
FTSE 100 up 0.8%, FTSE 250 adds 0.7%
Updated at 1600 GMT
By Shubham Batra and Roshan Abraham
Aug 15 (Reuters) -Britain's equity indexes rose on Thursday as global markets cheered data that allayed concerns of a recession in the United States, while the UK economy grew in line with expectations.
The blue-chip FTSE 100 .FTSE closed 0.8% higher and the midcap FTSE 250 .FTMC added 0.7%, both rising for a fifth consecutive session.
Britain's economy grew 0.6% in the second quarter of 2024, building on a rapid 0.7% recovery in the first quarter of the year after a shallow recession in the second half of 2023.
The pound GBP= rose 0.3% against the U.S. dollar, but money markets trimmed bets on the Bank of England cutting rates by 25 basis points in September to a 33% chance from 40% on Wednesday. 0#BOEWATCH
Benign U.S. consumer inflation data overnight had reinforced bets for the Federal Reserve to start cutting interest rates next month, while weekly jobless claims dropped to a one month low last week and retail sales increased by the most in nearly 1-1/2 years in July.
"The data has really helped to put to rest market participants' concerns about a potential U.S. recession," said Michael Brown, senior research strategist at Pepperstone.
Non-life insurers .FTNMX303020 were the top sectoral gainers with motor and home insurer Admiral Group ADML.L up 6.5% after posting a forecast-beating 32% rise in pre-tax profit for the first half of 2024 and saying it would pay a special dividend.
Industrial metal miners .FTNMX551020 were among the worst performers, clocking up losses for a third session as Rio Tinto RIO.L and Anglo American AAL.L traded ex-dividend, or without entitlement to their latest payouts.
Index heavyweight AstraZeneca AZN.L rose 2% after the U.S. Food and Drug Administration (FDA) granted its blockbuster cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.
Reporting by Shubham Batra and Roshan Abraham in Bengaluru; Editing by Eileen Soreng, Kirsten Donovan
For related prices, Reuters users may click on - * UK stock report .L FTSE index: 0#.FTS6 techMARK 100 index: .FTT1X FTSE futures: 0#FFI: Gilt futures: 0#FLG: Smallcap index: .FTSC FTSE 250 index: .FTMC FTSE 350 index: .FTLC Market digest: .AD.L Top 10 by vol: .AV.L Top price gainers: .NG.L Top % gainers: .PG.L Top price losers: .NL.L Top % losers: .PL.L * For related news, click on - * UK hot stocks: HOT and GB Wall Street: .N Gilts report: GB/ Euro bond report GVD/EUR Pan European stock report: .EU Tokyo stocks: .T HK stocks: .HK Sterling report: GBP/ Dollar report: USD/ * For company prices, click on - * Company directory: UKEQ By sector: FTAX * For pan-European market data, click on - * European Equities speed guide................ EUR/EQUITY FTSE Eurotop 300 index........................... .FTEU3 DJ STOXX index................................... .STOXX Top 10 STOXX sectors........................ .PGL.STOXXS Top 10 EUROSTOXX sectors................... .PGL.STOXXES Top 10 Eurotop 300 sectors.................. .PGL.FTEU3S Top 25 European pct gainers.................... .PG.PEUR Top 25 European pct losers..................... .PL.PEUR
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
